FTC seeks law against 'pay-for-delay' deals

WASHINGTON The chairman of the Federal Trade Commission and several members of Congress are calling for a law against deals that delay the launch of generic drugs onto the market.

FTC chairman Jon Leibowitz and Reps. Chris Van Hollen, D-Md., Bobby Rush, D-Ill., and Mary Jo Kilroy, D-Ohio, want to end so-called “pay-for-delay” deals, whereby branded drug companies pay generic drug companies in return for delaying the release of a generic drug.

“Pay-for-delay deals are a bad prescription for America: When drug companies agree not to compete, consumers lose,” Leibowitz said at a press conference. “Ending this practice as part of healthcare reform is one simple, effective and straightforward way for Congress to help control drug costs.”

According to a study by the FTC, the deals cost consumers an estimated $3.5 billion per year, while deals that involve payments by branded drug companies keep generics off the market for an average of 17 months longer than agreements that don’t include payments.

Login or Register to post a comment.